Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
AssigneeMedarex, Inc.
InventorsJosephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
Life of this patent
Estimating the term…
Abstract
Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
Claims6
1-62. (canceled)
A method for inhibiting the binding of type I interferon to IFN alpha receptor-1 on a cell expressing IFN alpha receptor-1 comprising contacting the cell with the humanized antibody or humanized antibody fragment that specifically binds IFN alpha receptor-1, comprising:
- a heavy chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3;
- and
- a light chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6;
- and
- variable domain framework regions from the heavy and light chains of a human antibody or human antibody consensus framework, wherein the variable domain framework regions are unaltered from the human antibody or human antibody consensus framework
- such that the binding of IFN to IFN alpha receptor-1 is inhibited.
67-83. (canceled)
Dependencies are inferred from the claim text.